Objectives: Dance as a non-pharmacological therapy is commonly used in dementia care, although the evidence of its effects remains unclear. This study systematically reviewed the effects of dance interventions on neuropsychiatric symptoms (NPS) in people living with dementia. To systematically identify and evaluate dance interventions, a standardized terminology for Dance-Specific Activity (DSA) is proposed.
Methods: Literature search was conducted on electronic databases until April 30 2021. Studies were included when they quantified the effects of DSA on NPS in people with clinical diagnosis of dementia. Included studies were analyzed in detail for NPS. Study quality was assessed by PEDro scale (German version).
Results: 4 studies were included. The studies differed in study design, intervention protocols, dance styles, or measurement tools, and were generally of low study quality. Two trials showed improvements in NPS and 2 trials showed no exacerbation of NPS after DSA.
Conclusions: The results of the 4 available trials indicate a positive tendency towards the effects of DSA, but considering the limitations of the few available studies, a clear statement about the effects of DSA is not possible yet. Based on the included trials, the following implications for clinical research and routine care can be derived: (1) DSA seems to be a practical terminology for identifying dance interventions (2) DSA seems to be a safe intervention for people living with dementia. (3) Different dance styles can be used. (4) DSA approaches should be better structured by differentiating between the domains
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/08919887221130268 | DOI Listing |
Nurs Leadersh (Tor Ont)
June 2025
Director and Professor, School of Nursing Assistant Dean, Research, Faculty of Health Dalhousie University Affiliate Scientist, Nova Scotia Health Affiliate Scientist, Maritime SPOR Support Unit Halifax, NS Co-Director, Canadian Centre for Advanced Practice Nursing Research Hamilton, ON.
and along with it, the first issue of the () for the year 2025. We begin the year with significant and persistent health and healthcare challenges. Recently released data from the Canadian Institute for Health Information indicate that 5.
View Article and Find Full Text PDFNord J Psychiatry
January 2025
Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Purpose: People living in supported accommodation often have complex care needs, including longer-term mental health illness and physical health comorbidities. Effective coordination between health and supported accommodation services is crucial to address these needs. However, evidence on the effectiveness of healthcare interventions in this setting remains limited.
View Article and Find Full Text PDFDev Med Child Neurol
January 2025
Cerebral Palsy Alliance Research Institute, Specialty of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Aim: To describe research priority-setting activities for cerebral palsy (CP) that have been conducted worldwide involving people with lived experience, focusing on participant characteristics, methods employed, identified research priorities, and collaboration as research partners.
Method: The JBI scoping review approach was followed. Six electronic databases and grey literature were searched for all publications up to February 2024.
Viruses
January 2025
1st Department of Internal Medicine, Laiko General Hospital, 11527 Athens, Greece.
Background: Cognitive function decline is a problem in aging people living with HIV (PLWHIV). COVID-19 infection is associated with neuropsychiatric manifestations that may persist. The aim of our study was to evaluate cognitive function in PLWHIV before and after COVID-19 infection.
View Article and Find Full Text PDFViruses
January 2025
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
Second-generation integrase strand transfer inhibitors (INSTIs) are strongly recommended for people living with HIV-1 (PLWH). The emergence of resistance to second-generation INSTIs has been infrequent and has not yet been a major issue in high-income countries. However, the delayed rollouts of these INSTIs in low- to middle-income countries during the COVID-19 pandemic combined with increased transmission of drug-resistant mutants worldwide are leading to an increase in INSTI resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!